Huang Hangkai, Liu Zhening, Xu Chengfu
Department of Gastroenterology, Zhejiang Provincial Clinical Research Centre for Digestive Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
Eur J Epidemiol. 2025 Apr 4. doi: 10.1007/s10654-025-01224-x.
This study aimed to investigate the association between aspirin use and the incidence of nonalcoholic fatty liver disease (NAFLD). We included 53,490 participants from the Nurses' Health Study II, a prospective US cohort study. Cox proportional hazard regression analyses were performed to assess the association between time-updated aspirin use and the risk of incident NAFLD. The exposure data included the status, duration, frequency and dosage of aspirin use. Data on the use of nonaspirin nonsteroidal anti-inflammatory drugs and acetaminophen were also collected. Over 1.1 million person-years of follow-up and 3,640 cases of incident NAFLD were documented. Compared with nonusers, current aspirin users had a significantly greater risk of NAFLD (HR: 1.17, 95% CI: 1.05 - 1.29). The current use of nonsteroidal nonaspirin anti-inflammatory drugs was also positively associated with NAFLD risk (HR: 1.29, 95% CI: 1.11 - 1.50). There were no significant associations with the use of acetaminophen. Aspirin use was associated with a modestly increased risk of incident NAFLD. These findings need to be confirmed in future studies.
本研究旨在调查阿司匹林使用与非酒精性脂肪性肝病（NAFLD）发病率之间的关联。我们纳入了来自美国护士健康研究II的53490名参与者，这是一项前瞻性队列研究。进行Cox比例风险回归分析，以评估随时间更新的阿司匹林使用与新发NAFLD风险之间的关联。暴露数据包括阿司匹林使用的状态、持续时间、频率和剂量。还收集了非阿司匹林非甾体抗炎药和对乙酰氨基酚的使用数据。记录了超过110万人年的随访以及3640例新发NAFLD病例。与未使用者相比，当前使用阿司匹林的人群患NAFLD的风险显著更高（风险比：1.17，95%置信区间：1.05 - 1.29）。当前使用非甾体非阿司匹林抗炎药也与NAFLD风险呈正相关（风险比：1.29，95%置信区间：1.11 - 1.50）。对乙酰氨基酚的使用未发现显著关联。阿司匹林使用与新发NAFLD风险适度增加相关。这些发现需要在未来的研究中得到证实。
